Victor Chang, MD

Current Trials

• Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma

  HIC ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028

  Recruiting Participants

  Lymphoma

• A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers

  HIC ID2000032270RoleSub InvestigatorPrimary Completion Date12/15/2027

  Recruiting Participants

  Head and Neck Cancers

• Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

  HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026

  Recruiting Participants

  Lung Cancer

• An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected With a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)

  HIC ID2000025449RoleSub InvestigatorPrimary Completion Date10/30/2023

  Recruiting Participants

  Breast Cancer

• Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors

  HIC ID2000032098RoleSub InvestigatorPrimary Completion Date03/31/2025

  Recruiting Participants

  Thyroid and Other Endocrine CancersPancreatic Cancer